July 2022 - an e-letter, estradiol, APPGs, inclisiran and nitrofurantoin

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July 2022 issue of DTB. They discuss the proposed reclassification of estradiol vaginal tablets from Prescription Only Medicine to a Pharmacy medicine (https://dtb.bmj.com/content/60/7/98) and review a study that assessed pharmaceutical industry funding of All Party Parliamentary Groups (https://dtb.bmj.com/content/60/7/100). They talk about the evidence for the lipid-lowering drug inclisiran and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/7/102). The editors also highlight a case report of acute lung toxicity caused by nitrofurantoin (https://dtb.bmj.com/content/60/7/108).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.